$LH

Kyle Kathryn W sold $26K of LH

Kyle Kathryn W (EVP, Chief Legal Officer) sold 92 shares of LABCORP HOLDINGS INC. (LH) at $286.19 on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kyle Kathryn W
Published Jul 6, 2026, 1:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 1:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LH
Neutral
high confidence
Mentioned
$LH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LHNeutralLow
01

Why it matters

Because the sale is explicitly under a pre-arranged Rule 10b5-1 plan, it typically reflects scheduled liquidity rather than new negative information.

02

Market read

A small, scheduled insider sale is unlikely to drive trading decisions beyond routine monitoring.

03

What to watch

The article provides only one transaction size and does not include prior insider activity frequency, option exercises, or any concurrent buys.

Relevance 2/10Novelty 3/10Timing: Filed July 6, covering a sale executed July 2

Background

The disclosure is an SEC Form 4 insider transaction by Kyle Kathryn W (EVP, Chief Legal Officer) for LABCORP HOLDINGS INC.

Company-level read

Ticker impact

$LHNeutralHigh confidence
Context

Form 4 shows LH’s EVP & Chief Legal Officer sold 92 shares at $286.19 on a 10b5-1 plan, totaling $26,329.48.

Expected impact

Minimal near-term impact; any effect is likely sentiment-only and short-lived.

Evidence & confidence

The filing is an open-market sale by an insider with an explicitly stated 10b5-1 plan and small share count/value relative to typical market moves.

Market effects

No clear sector read-through from a single, small 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal caution; traders may still monitor for a pattern.

Key entities

  • LABCORP HOLDINGS INC.

    Subject of the Form 4 insider transaction disclosure.

  • Kyle Kathryn W

    EVP, Chief Legal Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LHMed

Why Labcorp Holdings Stock Dropped Today

Labcorp Holdings (LH) stock fell 3.3% after CMS announced plans to cut lab reimbursement rates by up to 15% starting in 2027. CMS payments accounted for 8% of Labcorp's 2025 revenue, according to its SEC filing. The company warned that reduced rates could materially impact its revenue and profitability.

$BABAMed

Stocks making the biggest moves premarket: Alibaba, Quest Diagnostics, On Holding, GameStop & more

Alibaba shares rose 3% after its CEO announced plans for 20+ gigawatts of data centers by 2032 and launched a new chip. Quest Diagnostics and Labcorp fell 5% each due to Medicare payment adjustments. Vicor gained 9% on strong Q3 guidance. On Holding jumped 6% after setting new financial targets and a $1B share buyback plan. GameStop rose 3.5% after its CEO bought 1.2M shares.

$DGXMed

Premarket movers: Quest, Labcorp hit by CMS cuts

U.S. stock index futures steadied on Tuesday. Quest Diagnostics (DGX) fell 6.9% and Labcorp (LH) dropped 4.5% after CMS proposed cuts to lab reimbursements. On Holding (ONON) rose 6.4% on a $1B share buyback plan. Vicor (VICR) surged 9.9% after raising Q3 revenue outlook. Endava (DAVA) fell 12% due to CFO investigation. GameStop (GME) gained 3.5% after CEO bought shares. AnaptysBio (ANAB) rose 3.8% on better-than-expected revenue.

$LHMedAI 8/10

Why is Labcorp stock sliding today?

Labcorp (LH) stock fell 3.4% after-hours to $310 following CMS's proposal to cut Medicare lab reimbursements by up to 15% annually starting 2027. CMS claims this corrects overpayments, potentially saving $1B yearly. Truist raised its price target to $365 but kept a Buy rating. Quest Diagnostics faces similar headwinds. The selloff was sector-specific, with broader markets flat.